| Bioactivity | Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections[1][2]. |
| Invitro | Tefibazumab 具有由人 (>98%) 和鼠 (<2%) 氨基酸序列组成的可变抗原结合区。Tefibazumab 特异性识别金黄色葡萄球菌表达的 ClfA[2]。 |
| Name | Tefibazumab |
| CAS | 521079-87-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5. [2]. Reilley S, et, al. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother. 2005 Mar;49(3):959-62. |